Omnicell, Inc. (OMCL) Position Cut by UBS Group AG
UBS Group AG lowered its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 67.6% during the first quarter, Holdings Channel reports. The fund owned 2,497 shares of the company’s stock after selling 5,214 shares during the period. UBS Group AG’s holdings in Omnicell were worth $102,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of the stock. Renaissance Technologies LLC acquired a new position in Omnicell during the fourth quarter worth about $788,000. Norges Bank acquired a new position in Omnicell during the fourth quarter worth about $10,913,000. UBS Asset Management Americas Inc. boosted its position in Omnicell by 9.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 188,158 shares of the company’s stock worth $6,378,000 after buying an additional 15,779 shares during the last quarter. First National Bank of Omaha acquired a new position in Omnicell during the first quarter worth about $865,000. Finally, Juncture Wealth Strategies LLC boosted its position in Omnicell by 7.2% in the first quarter. Juncture Wealth Strategies LLC now owns 29,692 shares of the company’s stock worth $1,207,000 after buying an additional 1,998 shares during the last quarter. Institutional investors own 96.35% of the company’s stock.
Shares of Omnicell, Inc. (NASDAQ:OMCL) traded down 0.88% during midday trading on Tuesday, hitting $50.90. The company’s stock had a trading volume of 11,119 shares. Omnicell, Inc. has a 12-month low of $30.35 and a 12-month high of $51.97. The firm’s market cap is $1.91 billion. The firm has a 50-day moving average of $45.57 and a 200 day moving average of $41.37.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The business had revenue of $180.90 million during the quarter, compared to analyst estimates of $174.08 million. During the same period last year, the business posted $0.38 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. On average, equities research analysts predict that Omnicell, Inc. will post $1.31 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/omnicell-inc-omcl-position-cut-by-ubs-group-ag/1491704.html.
OMCL has been the subject of a number of recent analyst reports. Piper Jaffray Companies cut Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 price objective for the company. in a report on Friday, April 21st. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $53.00 price objective (up previously from $43.00) on shares of Omnicell in a report on Tuesday, April 25th. CIBC boosted their price objective on Omnicell from $43.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday, April 26th. TheStreet cut Omnicell from a “b-” rating to a “c+” rating in a report on Thursday, May 4th. Finally, Zacks Investment Research cut Omnicell from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $49.00.
In other news, EVP Dan S. Johnston sold 16,400 shares of the firm’s stock in a transaction on Friday, May 19th. The stock was sold at an average price of $40.67, for a total transaction of $666,988.00. Following the completion of the transaction, the executive vice president now directly owns 61,696 shares in the company, valued at $2,509,176.32. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Peter J. Kuipers sold 18,054 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $50.31, for a total value of $908,296.74. Following the transaction, the vice president now owns 44,236 shares of the company’s stock, valued at $2,225,513.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 199,823 shares of company stock valued at $9,301,391. Company insiders own 3.77% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.